Kala Pharmaceuticals

Kala Bio, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The firm is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.